Shionogi

Deal making
#Mergers and acquisitions #Neurodegenerative disorders #Rare disease #Shionogi

Shionogi expands rare disease portfolio with IntraBio buyout

Shionogi has announced plans to acquire IntraBio, a biopharmaceutical company developing therapies for neurodegenerative diseases, for $2 billion.  The transaction will add Aqneursa (levacetylleucine) and IntraBio’s capabilities in the rare disease area to Shionogi’s growing portfolio.  Aqneursa was approved by the FDA in September 2024… Read More

#Business & Investment #News